Back to Oncology
Oncologyv2019Evidence-Based

PSA Doubling Time (PSADT) Calculator

Calculates PSA doubling rate in prostate cancer patients with biochemical recurrence after treatment. This prognostic tool correlates with survival and helps guide treatment decisions for salvage therapy, imaging studies, and castration-resistant disease management. Uses longitudinal PSA measurements to determine the rate of PSA increase over time.

Clinical Input Parameters

ng/mL
Range: 0.01 — 10000 ng/mL
days
Range: 0 — 10000 days
ng/mL
Range: 0.01 — 10000 ng/mL
days
Range: 0 — 10000 days
ng/mL
Range: 0.01 — 10000 ng/mL
days
Range: 0 — 10000 days
ng/mL
Range: 0.01 — 10000 ng/mL
days
Range: 0 — 10000 days
ng/mL
Range: 0.01 — 10000 ng/mL
days
Range: 0 — 10000 days
Clinical Assessment
Awaiting Parameters
psa doubling time
—months
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The PSA Doubling Time (PSADT) Calculator is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within oncology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

PSADT = ln(2) / slope, where slope is derived from linear regression of ln(PSA) vs time

Clinical Pearls & Practice Notes

  • Used only for patients with biochemical recurrence after treatment
  • Requires at least 2 PSA measurements, preferably 3 or more for accuracy
  • Not applicable for initial prostate cancer screening or untreated patients
  • PSA doubling time <6 months associated with worse prognosis
  • PSA doubling time >12 months associated with better survival
  • Should be used in conjunction with Gleason score and other clinical factors
  • Helps guide decisions for salvage therapy and imaging studies
  • Multiple measurement points improve calculation accuracy
  • Consider measurement errors and laboratory variability
  • Time intervals should be adequate to detect PSA changes (usually ≥3 months)
  • Used for monitoring castration-resistant prostate cancer progression
  • May guide timing of systemic therapy initiation

Evidence & Literature Citations

  1. D'Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst. 2003;95(18):1376-83. doi: 10.1093/jnci/djg043.
  2. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294(4):433-9. doi: 10.1001/jama.294.4.433.
  3. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281(17):1591-7. doi: 10.1001/jama.281.17.1591.
  4. Zhou P, Chen MH, McLeod D, Carroll PR, Moul JW, D'Amico AV. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol. 2005;23(28):6992-8. doi: 10.1200/JCO.2005.01.2906.

Score Interpretation Ranges

Very High Risk0 – 3 pts

Rapid PSA progression

High Risk3 – 6 pts

Fast PSA progression

Intermediate Risk6 – 12 pts

Moderate PSA progression

Low Risk12 – 36 pts

Slow PSA progression

Very Low Risk36 – 1000 pts

Very slow PSA progression

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.